Abiraterone Acetate
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.
Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial
National Prostate Cancer Awareness Month is observed every September.
Mark Cuban company could yield savings on seven Medicare generic oncology drugs
Mark Cuban Cost Plus Drug Company’s pricing could yield significant savings for seven generic oncology drugs vs. Medicare Part D median formulary prices, according to study results published in Journal of Clinical Oncology.
Recent developments in advanced prostate cancer space pave way for future breakthroughs
Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.
Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset
CHICAGO Adding prostate irradiation to standard systemic therapy extended radiographic PFS among men with newly diagnosed low-volume metastatic castration-sensitive prostate cancer, according to results of the PEACE-1 trial.
FDA approves Lynparza regimen for certain men with BRCA-positive prostate cancer
The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
FDA committee favors restricting prostate cancer regimen to BRCA-positive subgroup
An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.
Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations
SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.
Rucaparib improves radiographic PFS in prostate cancer subgroup
SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.
Rucaparib extends PFS in advanced prostate cancer
A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.